U.S. Markets closed

Should You Worry About Antibe Therapeutics Inc.'s (CVE:ATE) CEO Salary Level?

Simply Wall St

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

Dan Legault became the CEO of Antibe Therapeutics Inc. (CVE:ATE) in 2009. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, we'll consider growth that the business demonstrates. Third, we'll reflect on the total return to shareholders over three years, as a second measure of business performance. This process should give us an idea about how appropriately the CEO is paid.

View our latest analysis for Antibe Therapeutics

How Does Dan Legault's Compensation Compare With Similar Sized Companies?

According to our data, Antibe Therapeutics Inc. has a market capitalization of CA$80m, and pays its CEO total annual compensation worth CA$273k. (This figure is for the year to March 2018). Notably, the salary of CA$273k is the vast majority of the CEO compensation. We looked at a group of companies with market capitalizations under CA$264m, and the median CEO total compensation was CA$152k.

As you can see, Dan Legault is paid more than the median CEO pay at companies of a similar size, in the same market. However, this does not necessarily mean Antibe Therapeutics Inc. is paying too much. A closer look at the performance of the underlying business will give us a better idea about whether the pay is particularly generous.

You can see a visual representation of the CEO compensation at Antibe Therapeutics, below.

TSXV:ATE CEO Compensation, June 24th 2019

Is Antibe Therapeutics Inc. Growing?

On average over the last three years, Antibe Therapeutics Inc. has grown earnings per share (EPS) by 2.9% each year (using a line of best fit). In the last year, its revenue is up 8.6%.

I'm not particularly impressed by the revenue growth, but I'm happy with the modest EPS growth. Considering these factors I'd say performance has been pretty decent, though not amazing. You might want to check this free visual report on analyst forecasts for future earnings.

Has Antibe Therapeutics Inc. Been A Good Investment?

I think that the total shareholder return of 141%, over three years, would leave most Antibe Therapeutics Inc. shareholders smiling. As a result, some may believe the CEO should be paid more than is normal for companies of similar size.

In Summary...

We compared total CEO remuneration at Antibe Therapeutics Inc. with the amount paid at companies with a similar market capitalization. As discussed above, we discovered that the company pays more than the median of that group.

Over the last three years returns to investors have been great, though we might have liked stronger business growth. So, considering these tasty returns, the CEO compensation may be quite appropriate. If you think CEO compensation levels are interesting you will probably really like this free visualization of insider trading at Antibe Therapeutics.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.